[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropsychology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropsychology":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,87,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100596630","neuropsychological-evaluation-in-intellectual-disability-endi-100596630",false,"NCT07047963","Neuropsychological Evaluation in Intellectual Disability (ENDI)","Neuropsychological Evaluation in Intellectual Disability","ENDI","Inclusion Criteria:\n\nPreliminary phase:\n\n1. The inclusion criteria for the group of people with intellectual disabilities are as follows:\n\n   * Participant who has received full information on the organization of the research and has not objected to his or her participation and to the use of his or her data.\n   * Legal guardian of the participant, if applicable, who has received full information on the organization of the research and has not objected to participation and use of his\u002Fher data.\n   * Age at inclusion: ≥ 25 and ≤ 65 years\n   * Notion of intellectual disability in medical records\n   * Access to the oral language of the participant with an intellectual disability: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \\& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.\n   * Enrolled in or benefiting from a social security scheme.\n2. The inclusion criteria for the normotypic group are as follows:\n\n   * Participant having received full information on the organization of the research and not having objected to his or her participation and to the use of his or her data.\n   * Age at inclusion: ≥ 25 and ≤ 65 years\n   * Affiliation with a social security scheme or beneficiary of such a scheme\n\nMain phase:\n\nInclusion criteria are as follows:\n\n* Participant with T21 who has received full information on the organization of the research and has not objected to participation and use of his\u002Fher data\n* Legal guardian of the participant with T21, where applicable, who has received full information on the organization of the research and has not objected to his or her participation and the use of his or her data.\n* Person with trisomy 21\n* Age at inclusion: ≥ 25 and ≤ 65 years\n* Access to the oral language of the participant with T21: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \\& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.\n* Membership of a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria for both phases of the study are as follows:\n\n* Disabling motor and\u002For sensory impairments preventing completion of the tests\n* Insufficient command of the French language to complete the tests\n* Severe general medical condition or alcoholism (habitual consumption of 3 drinks\u002Fday or history of alcohol withdrawal)\n* History of stroke, severe head trauma, or cancer\n* Change in long-term medication within 8 weeks prior to evaluation\n* Refusal to participate by the subject and\u002For legal representative\n* Individuals referred to in Articles L.1121-5 to L.1121-7 of the French Public Health Code:\n\n  * Pregnant women, women in labor, or breastfeeding mothers\n  * Individuals deprived of liberty by judicial or administrative decision\n  * Individuals undergoing psychiatric treatment under Article L.3213-1 of the French Public Health Code",true,"ALL","25 Years","65 Years",{"count":22,"type":23},40,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.\n\nIn this study, three types of population will be recruted : normotypic volunteers, patients with Intellectual Disability and patients T21carriers.\n\nThis study is separated into 2 phases :\n\n* A the preliminary phase : this phase will be used to evaluate subtest design, ergonomics and understanding of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company. In this phase, normotypical volunteers and patients with intellectual disabilities will be recruted to perform ENDI test battery.\n* A main phase : this phase will enable to answer to the main objective. in this phase, patients with Trisomy 21 aged between 25 and 65 will be recruted to perform ENDI test battery.",[27,28,29,30,31],"Down Syndrome (Trisomy 21)","Neuropsychology","Cognitive Aging","Alzheimer Disease","Alzheimer Disease, Early Onset",[27,15,33,34,35],"Trisomy 21","neuropsychology","ENDI tests battery","NOT_YET_RECRUITING","2025-06-24",{"date":39,"type":40},"2025-07-02","ACTUAL",{"date":42,"type":23},"2025-07-01",{"date":44,"type":23},"2026-11-01",{"name":46,"class":47},"Central Hospital, Nancy, France","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},"100571346","effect-of-immersive-virtual-reality-with-multisensory-stimulation-on-the-functional-impact-of-hemineglect-secondary-to-a-right-sided-stroke-100571346","NCT06719063","Effect of Immersive Virtual Reality With Multisensory Stimulation on the Functional Impact of Hemineglect Secondary to a Right-Sided Stroke","Effect of Immersive Virtual Reality With Multisensory Stimulation on the Functional Impact of Hemineglect Secondary to a Right-Sided Stroke: A Single Case Experimental Design (SCED) Study","NEGLISENS","Inclusion Criteria:\n\n* Patient aged over 18 years\n* Diagnosis of first ischemic right stroke established by a neurologist using clinical examination and brain imaging (CT scan or MRI)\n* Stroke occurring less than 3 months ago\n* Presence of left hemineglect, diagnosed using the Neglect Assessment Battery (NAB)\n* Normal vision or corrected to normal\n* Patient affiliated with the social security system\n\nExclusion Criteria:\n\n* History of neurological or psychiatric illness\n* Epilepsy\n* Craniotomy\n* Limited range of cervical motion due to orthopedic disorders\n* Moderate or severe deafness (hearing loss of 40 dB in one ear, as measured by tonal audiometry)\n* Anosmia (loss of smell)\n* Asthmatic disease\n* Pregnant women or women suspected of being pregnant\n* Breastfeeding women\n* Severe neurocognitive disorders with an MMSE score \\\u003C 21\n* Patient under legal protection measures\n* Minor patient\n* Patient enrolled in another research protocol","18 Years",{"count":59,"type":23},3,"INTERVENTIONAL",[62],"NA","A stroke is a common and potentially serious condition that affects 130,000 people each year in France. It is the second leading cause of major cognitive disorders after Alzheimer's disease.\n\nHemineglect is a frequently observed cognitive impairment following a stroke. The individual becomes unable to orient themselves or respond to stimuli appearing in the contralesional hemispace. Hemineglect occurs in approximately 25-30% of stroke patients, with the right hemisphere being affected in 90% of cases.\n\nDespite potential spontaneous recovery within the first 2 to 3 months post-stroke, neglect tends to persist chronically. One-third of patients suffer from long-term neglect. The condition is more severe after a right-sided lesion. The functional impact is significant, particularly when considering the anosognosia and anosodiaphoria often associated with it. Rehabilitation stays are longer for patients with neglect, and autonomy in daily activities is reduced. Neglect leads to poorer functional outcomes after a stroke, making it a critical factor to address in a patient's rehabilitation program.\n\nThe goal of rehabilitation is to reduce impairments, improve activity limitations and participation restrictions secondary to hemineglect, and achieve functional progress beyond what is possible through spontaneous recovery. Since no single rehabilitation method for neglect is superior to another, it is currently recommended to combine multiple approaches.\n\nThe top-down approach is based on intention and conscious effort. This technique is among the first used for neglect rehabilitation and remains widely used today. The goal is to help the patient become aware of their neglectful behavior.\n\nThe bottom-up approach relies on more automatic mechanisms of action and aims to modulate the spatial reference system through passive sensory manipulations or visuomotor adaptation.\n\nThe use of virtual reality in stroke rehabilitation promotes plasticity and neural reorganization. In the field of hemineglect, several studies have examined the effects of virtual reality using top-down and\u002For bottom-up approaches and have shown significant functional improvements. In the case of multisensory stimulation, delivering different stimuli to the same side of space and at the same time increases neuronal activity, leading to a stronger clinical response than unisensory stimulation.\n\nThe VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion is achieved through the simultaneous stimulation of four out of the five senses. Firstly, vision and hearing are stimulated by a virtual reality headset that projects high-definition films. Smell is activated through the release of micro-droplets of fragrances synchronized with the imagery. Finally, touch is stimulated by warm and cold airflows that enhance the various scenes presented.\n\nThe investigators emit the hypothesis that the VirtySens® capsule, immersive virtual reality combining multisensory stimulation via four of the five senses and training in visual scanning, introduced in rehabilitation, allows to significantly reduce the functional impact of hemineglect in the adult victim of a right cerebral infarction dating less than 3 months.\n\nTo respond to these research objectives, the investigators will carry out a pilot study in Single Case Experimental Design (SCED). The experimentation will take place in mainland France within La Musse hospital. The recruitment of 3 subjects will be necessary for the realization of this study.\n\nThe study will consist of repeated evaluation and rehabilitation sessions. Evaluations will be conducted at La Musse Hospital by an occupational therapist. The purpose of the evaluation sessions is to measure the impact of hemineglect on autonomy. This measurement will be performed using the Catherine Bergego Scale, which will be completed by both the patient and the occupational therapist. Evaluation sessions will last approximately 45 minutes and will take place once a week for 10 to 12 weeks.\n\nAfter 3 to 5 weeks of evaluations, the patient will participate in three weekly rehabilitation sessions, each lasting 45 minutes, over a 5-week period. These sessions will be individual and conducted by an occupational therapist. Each session will follow a similar structure: review of the previous session, explanation of the current session, a 15-minute multisensory experience using virtual reality, followed by a review of the session, particularly focusing on tolerance.",[65,66,28,67,68,69],"Stroke","Hemineglect","Virtual Reality","Rehabilitation","Immersion",[71,72,34,73,74,75,76],"stroke","hemineglect","virtual reality","rehabilitation","multisensory","immersion","RECRUITING","2025-05-09",{"date":80,"type":40},"2025-05-11",{"date":82,"type":40},"2025-04-04",{"date":84,"type":23},"2025-08-31",{"name":86,"class":47},"Hopital La Musse",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":95,"targetDuration":97,"studyType":24,"phases":4,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100580391","effect-of-the-new-definition-of-epilepsies-of-the-ilae-of-2014-on-the-diagnosis-after-the-first-seizure-100580391","NCT06836687","Effect of the New Definition of Epilepsies of the ILAE of 2014 on the Diagnosis After the First Seizure","Monocentric Study to Investigate the Effect of the New Definition of Epilepsies of the International League Against Epilepsy of 2014 on the Diagnosis After the First Seizure, on Patient Satisfaction, Cognition and Health Economic Factors","EFS-ILAE2014","Inclusion Criteria:\n\n* Completion of the 18th year of life\n* first epileptic seizure\n* Ability to understand the patient information and to give written consent\n* Written consent for voluntary participation in the study\n\nExclusion Criteria:\n\n* Chronic drug or alcohol abuse in the last two years",{"count":96,"type":23},1000,"10 Years","The present study is a prospective study on the development of seizure frequency, medication adherence, quality of life and cognitive performance after a first epileptic seizure using the new diagnostic criteria for epilepsy of the International League Against Epilepsy of 2014 at the time of diagnosis.",[100,28,101],"Seizure, Epileptic","Outcome",[103,104,28,105],"First epileptic seizure","Definition of epilepsy","outcome","2025-02-18",{"date":108,"type":40},"2025-02-20",{"date":110,"type":40},"2018-03-01",{"date":112,"type":23},"2038-08-01",{"name":114,"class":47},"University Hospital Marburg",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":60,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100490571","longitudinal-neurocognitive-psychosocial-and-health-related-quality-of-life-assessment-in-advanced-cancer-survivors-treated-with-immunotherapy-and-the-efficacy-of-integrative-neurocognitive-remediation-therapy-100490571","NCT05667857","Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy","CognIT","Inclusion Criteria:\n\n1. Non-intervention group:\n\n   * Provision of written informed consent\n   * Diagnosed with advanced cancer of any type\n   * Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, …) at least one year ago\n   * Have a confirmed normalization on whole-body 18F-FDG PET\n   * English, Dutch or French-speaking\n2. Integrative neurocognitive remediation therapy group:\n\n   * Provision of written informed consent\n   * Objective cognitive impairment and\u002For subjective cognitive complaints\n   * Confirmed normalization on whole-body 18F-FDG PET for patients (cohort 1)\n   * Disease-free (cohort 2) or no active disease for patients with CNS tumors (cohort 3)\n   * Having received a cancer therapy of any kind\n   * Having ended cancer treatment (immunotherapy, chemotherapy, radiotherapy, surgery, …) with an exception of ongoing adjuvant hormone therapy\n   * Dutch or French speaking\n\nExclusion Criteria:\n\n* severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with cognitive impairment related to dementia, and patients that are physically or mentally not able to fill in the questionnaires",{"count":123,"type":23},100,[62],"Since 2010, the field of immunotherapy has grown substantially, leading to a growing population of long-term cancer survivors treated with immunotherapy. Since cancer survivorship in immunotherapy is an emerging field, to date not much is known about psychosocial and neurocognitive survivorship-related issues in advanced cancer survivors treated with immunotherapy. Preliminary findings indicated significant psychosocial and cognitive problems in survivors of advanced melanoma persist after treatment with immunotherapy. The objective for this project is twofold. First, the investigators want to longitudinally identify survival-related problems in survivors of advanced cancer treated with immunotherapy. The second goal is to identify the efficacy of an Integrative Neuro-Cognitive Remediation Therapy (INCRT) program. The investigators will focus on the following outcomes: (1) Psychosocial consequences, such as emotional complaints, fatigue, fear of recurrence, (2) neurocognitive functioning, and (3) health-related quality of life. The INCRT combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of exercise, mindfulness, Acceptance and Commitment Therapy, and cognitive behavioral therapy.\n\nWe will have three cohorts:\n\n* Cohort 1: advanced cancer survivors treated with immunotherapy\n* Cohort 2: cancer survivors treated with cancer therapy of any kind (excluded immunotherapy), and who have subjective complaints and\u002For objective cognitive impairment\n* Cohort 3: cancer survivors of a central nervous system (CNS) tumor, who do not have active disease in the CNS, and who have subjective complaints and\u002For objective cognitive impairment\n\nIn the first part of the study, survival-related problems will be evaluated in cohort 1, in a longitudinal manner by means of a semi-structured interview at baseline, various questionnaires and a computerized neuropsychological test battery.\n\nIn the second part of the study, patients of cohort 1, 2 and 3 with subjective or objective cognitive dysfunction can follow the INCRT program. The efficacy of the INCRT is evaluated through a pre-INCRT and post-INCRT evaluation. This evaluation consist of several questionnaires and neuropsychological tests. Long-term efficacy will be evaluated by a follow-up evaluation six months after completion of the INCRT program.",[127,28,128,129,130,131,132,133,134],"Cognitive Remediation","Quality of Life","Psycho-Oncology","Cognitive Behavioral Therapy","Cancer Survivors","Immunotherapy","Cognitive Dysfunction","Psychological Distress","2025-01-16",{"date":137,"type":40},"2025-01-20",{"date":139,"type":40},"2022-07-13",{"date":141,"type":23},"2033-12",{"name":143,"class":47},"Universitair Ziekenhuis Brussel",2]